Choosing a Treatment for Benign Prostatic Hyperplasia (BPH): What Makes the Difference?

There are many treatments available for benign prostatic hyperplasia (BPH), or an enlarged prostate. The spectrum extends from medical intervention, to minimally invasive procedures and surgery and each available treatment differs in how they work, their potential effects on sexual function, recovery time, and the likelihood of needing further treatment.

That which works well for one man may not be suitable for another, even if they report similar urinary symptoms. For example, a patient with a moderately enlarged prostate who wants to preserve ejaculation may have different options from an older man with a very large prostate, recurrent urinary retention, and several other medical conditions.

Choosing a treatment initially involves measuring prostate size and the extent of symptoms. Doctors also consider the shape of the prostate, bladder function, overall health, sexual priorities, and the possibility that the patient might need re-treatment. The right approach depends on how these factors apply to each individual.

Knowing what influences treatment selection can help you look beyond prostate size alone and understand which options best fit your symptoms, health, and priorities.

Age and overall health
Age can influence treatment decisions, but it does not determine them on its own. If a patient in his seventies is otherwise healthy he could very well be suitable for surgery, while a younger man with comorbidities like heart or lung disease may need a less invasive approach. Generally, for older men, doctors consider physical fitness, frailty, mobility, cognitive function, other medications, and the risks associated with anaesthesia and recovery. If symptoms are mild and there are no complications, monitoring or medication may be appropriate. If the prostate is causing repeated urinary retention, infections, bladder stones, or kidney problems, a procedure may be necessary even in someone with substantial medical risks.

Men with conditions such as heart disease, diabetes, kidney disease, or a history of stroke require an individual assessment. Blood thinners, in particular, can affect procedural planning because some treatments carry a greater bleeding risk than others. Laser procedures such as HoLEP may be considered in selected patients at increased bleeding risk. PAE may also be discussed when avoiding conventional prostate surgery or general anaesthesia is a priority.

Prostate size and shape
Prostate volume narrows down the range of appropriate treatments. It is usually measured using ultrasound or other imaging, with volume commonly expressed in cubic centimetres (cc).

For small prostates around 30 cc or less, a transurethral incision of the prostate (TUIP) may be suitable in selected cases. Medication is often prescribed depending on how severe the symptoms are. Prostatic artery embolization (PAE) is generally not the first choice in this size range, since the smaller gland offers less to treat and other options tend to be simpler and better established.

For moderately enlarged prostates, roughly 30 to 80 cc, the range of options widens to include medication, UroLift, Rezum, TURP, and PAE. For this range, PAE can be particularly effective as it is a minimally invasive, catheter-based approach that reduces blood flow to the gland, causing it to shrink over time without any cutting or heating of the urethra. It can be attractive for men who wish to avoid surgery, who are higher-risk surgical candidates, or who place a high priority on preserving sexual function and ejaculation. The final choice depends on prostate anatomy, the degree of obstruction, the patient's sexual priorities, and the desired immediacy of symptom relief.

For large prostates, above 80 cc, HoLEP is an established option that works across a wide range of prostate sizes and is often favored for its durable results. Other surgical procedures or simple prostatectomy may also be considered, depending on the size of the gland, local expertise, and the patient's overall health. PAE can likewise be considered in appropriately selected patients, and it is especially useful for those who are poor candidates for surgery or anesthesia, or who wish to avoid an operation.

These ranges are guides rather than strict boundaries. For example, PAE and HoLEP can be used for very large prostates, whereas UroLift and Rezum have commonly studied treatment ranges of approximately 30–80 cc.

The shape of the prostate matters as well. Enlargement of the middle lobe, for example, can cause tissue to protrude into the bladder and influence whether a non-surgical BPH treatment procedure is suitable. UroLift, for example, has specific anatomical considerations, while other procedures may accommodate a wider range of prostate shapes. Ultrasound, and sometimes cystoscopy (a procedure to help see the inside of the bladder and urethra) or other imaging, can help clinicians assess the prostate's anatomy before treatment. This information is particularly important when choosing a procedure with specific anatomical requirements.

Severity of symptoms and bladder function
The size of the prostate does not always correspond to the severity of urinary symptoms. A comparatively small gland can cause significant obstruction; a larger prostate may cause fewer symptoms. Frequent urination and urgency can occur due to an overactive bladder. If the prostate grows large enough to obstruct the outlet, patients will have difficulty passing urine. These problems can also occur together. Long-standing obstruction can affect the bladder's ability to contract and empty. If bladder muscle function has deteriorated, treating the prostate may improve the obstruction without completely restoring normal urination.

Patients experiencing mild symptoms that do not substantially affect daily life may be able to start with monitoring, lifestyle adjustments, or medication. Those with symptoms that continue despite medication benefit from a procedure.

The decision changes when complications develop. Recurrent urinary retention, repeated urinary tract infections, bladder stones, or kidney impairment caused by obstruction may make procedural treatment more important. Doctors also assess how well the bladder contracts, because removing or reducing the obstruction may not fully restore normal urination if bladder function has already deteriorated.

When is medication enough?

Men with mild or moderate symptoms and no significant complications may be able to manage BPH with monitoring, lifestyle adjustments, or medication. Alpha-blockers relax muscles around the prostate and bladder neck, making it easier to pass urine. They can improve symptoms relatively quickly but do not shrink the prostate.

Finasteride and dutasteride reduce the effects of hormones that contribute to prostate growth. In suitable men with enlarged prostates, these medicines can gradually reduce prostate volume and lower the risk of urinary retention. They take longer to work and can cause sexual side effects.

Some men benefit from a combination of medicines. Others may need to consider a procedure if symptoms remain troublesome, medication causes unacceptable side effects, or complications develop.

Recurrent urinary retention, repeated urinary tract infections, bladder stones, significant bleeding attributed to BPH, or kidney problems caused by obstruction can make procedural treatment necessary. These findings require clinical assessment rather than relying on symptom severity alone.

Sexual function, fertility, and personal priorities

Sexual function is an important consideration when choosing BPH treatment. Patients will definitely have different priorities around ejaculation, erections, sexual desire, and fertility at different stages of their life, and these should be discussed separately.

The treatments differ in their effects:

• UroLift: Uses small implants to hold prostate tissue away from the urethra. Ejaculation and erectile function are generally well preserved in appropriately selected patients.
• Rezum: Uses water vapour to treat enlarged prostate tissue. Many men retain ejaculatory function, although changes can occur.
• PAE: Reduces blood flow to the prostate rather than removing tissue. Studies generally report fewer ejaculatory changes than TURP, although individual outcomes vary.
• TURP and HoLEP: Remove obstructing prostate tissue and commonly cause retrograde ejaculation or other changes in ejaculation. Erectile function is often maintained, but erectile difficulties remain possible.

Men who wish to father children should also discuss fertility before treatment. Retrograde ejaculation or a major reduction in semen volume can affect the ability to conceive naturally, even when erections and orgasm are preserved.

Needing further treatment

Treatment options differ in how they relieve obstruction, how quickly symptoms improve, and the likelihood of needing another procedure.

PAE, UroLift and Rezum are appealing if patients want to avoid conventional tissue-removing surgery and prioritise preservation of ejaculation, provided their prostate anatomy is suitable. Symptom improvement and recovery differ between the three procedures.

TURP removes obstructing tissue through the urethra, while HoLEP uses a laser to separate and remove it. Both have established roles in treating urinary obstruction. HoLEP can be used across a wide range of prostate sizes, including large glands.

For a younger man who may live with BPH for several decades, the possibility of future treatment may carry particular importance. An older man with significant medical conditions may place greater emphasis on the immediate risks of a procedure, recovery time, and avoiding general anaesthesia where appropriate. These are individual considerations rather than rules based on age.

What tests determine the right treatment?

Before recommending a procedure, clinicians generally review the symptom history, medication use, urine test results, prostate volume and anatomy, and the amount of urine left in the bladder after urination. Urine-flow testing and additional investigations may be appropriate when the cause of symptoms or the degree of obstruction is unclear.

These findings help distinguish those whose symptoms are likely to improve with medication from those who may benefit from a procedure. They also help identify patients who need more urgent treatment because of complications.

Depending on the clinical situation, the assessment may include:

• Symptom assessment: A review of urinary symptoms, their effect on daily life, and response to medication. The International Prostate Symptom Score (IPSS) may be used to measure symptom severity.
• Urine testing: Helps identify infection, blood, or other urinary abnormalities.
• Prostate assessment: Examination and imaging can help determine prostate size and shape. PSA testing may be appropriate depending on the clinical context.
• Bladder assessment: Urine-flow testing and measurement of the urine remaining after urination can help identify impaired emptying.
• Further investigations: Cystoscopy or urodynamic testing may be recommended when the diagnosis is uncertain or additional information is needed for treatment planning.

Not every man needs every test. The investigations are selected according to symptoms, medical history, examination findings, and the treatment being considered.

Comparing the main BPH treatment options

Why choose RIVEA for PAE?

At RIVEA Vascular Institute in Hyderabad, prostate artery embolization is performed by interventional radiologists using advanced image-guided technology. PAE offers an alternative to conventional prostate surgery for appropriately selected men with BPH.

The team is led by Dr. Arjun Reddy, Co-founder and Chief Interventional Radiologist at RIVEA, who performed Hyderabad's first PAE at AIG Hospitals.

RIVEA offers:

• Advanced imaging: The Allia IGS 7 hybrid imaging system supports image-guided embolization.
• Minimally invasive treatment: PAE is performed through a small arterial access point without surgically removing prostate tissue.
• Individualised assessment: Prostate anatomy, urinary symptoms, overall health, and sexual function priorities help guide treatment planning.
• Support throughout care: Patients receive guidance from initial assessment through recovery and follow-up.